Switch to:
Also traded in: Germany, Switzerland

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt No Debt
ORMP's Cash-to-Debt is ranked higher than
87% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. ORMP: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
ORMP' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.06  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.51
ORMP's Equity-to-Asset is ranked lower than
68% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. ORMP: 0.51 )
Ranked among companies with meaningful Equity-to-Asset only.
ORMP' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.51  Med: 0.61 Max: 0.85
Current: 0.51
0.51
0.85
Piotroski F-Score: 5
Altman Z-Score: 1.43
Beneish M-Score: 6.84
WACC vs ROIC
8.47%
-56.17%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -656.99
ORMP's Operating Margin % is ranked lower than
74% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. ORMP: -656.99 )
Ranked among companies with meaningful Operating Margin % only.
ORMP' s Operating Margin % Range Over the Past 10 Years
Min: -1561.62  Med: -1561.62 Max: -1561.62
Current: -656.99
Net Margin % -723.95
ORMP's Net Margin % is ranked lower than
77% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. ORMP: -723.95 )
Ranked among companies with meaningful Net Margin % only.
ORMP' s Net Margin % Range Over the Past 10 Years
Min: -1710.45  Med: -1710.45 Max: -1710.45
Current: -723.95
ROE % -46.51
ORMP's ROE % is ranked lower than
54% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. ORMP: -46.51 )
Ranked among companies with meaningful ROE % only.
ORMP' s ROE % Range Over the Past 10 Years
Min: -8090  Med: -73.14 Max: -31.7
Current: -46.51
-8090
-31.7
ROA % -30.78
ORMP's ROA % is ranked higher than
50% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. ORMP: -30.78 )
Ranked among companies with meaningful ROA % only.
ORMP' s ROA % Range Over the Past 10 Years
Min: -306.29  Med: -61.8 Max: -30.04
Current: -30.78
-306.29
-30.04
ROC (Joel Greenblatt) % -55.47
ORMP's ROC (Joel Greenblatt) % is ranked higher than
67% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. ORMP: -55.47 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ORMP' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -313200  Med: -224.73 Max: 5234
Current: -55.47
-313200
5234
3-Year EBITDA Growth Rate 7.10
ORMP's 3-Year EBITDA Growth Rate is ranked higher than
57% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. ORMP: 7.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ORMP' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -10.7  Med: 7.1 Max: 57.2
Current: 7.1
-10.7
57.2
3-Year EPS without NRI Growth Rate 13.80
ORMP's 3-Year EPS without NRI Growth Rate is ranked higher than
67% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. ORMP: 13.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ORMP' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -26.3  Med: 5.5 Max: 188.4
Current: 13.8
-26.3
188.4
GuruFocus has detected 2 Warning Signs with Oramed Pharmaceuticals Inc $ORMP.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ORMP's 30-Y Financials

Financials (Next Earnings Date: 2017-07-06 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with ORMP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:SBPH, NAS:CBAY, NAS:ZFGN, NAS:MNKD, NAS:CDTX, NAS:ECYT, NAS:VVUS, NAS:AFMD, NAS:GEMP, NAS:ADVM, NAS:SRNE, OTCPK:CTIX, OTCPK:VNLPY, NAS:PRQR, OTCPK:INNMF, AMEX:RNN, NAS:ARWR, NYSE:KDMN, AMEX:PLX, AMEX:XXII » details
Traded in other countries:OJU1.Germany, ORMP.Switzerland,
Headquarter Location:Israel
Oramed Pharmaceuticals Inc is a pharmaceutical company. The Company is engaged in the research and development of pharmaceutical solutions, including an orally ingestible insulin capsule or tablet.

Oramed Pharmaceuticals Inc was incorporated on April 12, 2002, under the laws of the state of Nevada. It is a pharmaceutical company engaged in the research and development of pharmaceutical solutions, including an orally ingestible insulin capsule or tablet to be used for the treatment of individuals with diabetes, rectal application of insulin, use of oral ingestible capsules or tablets for delivery other polypeptides and use of rectal application for delivery of other polypeptides. It filed two additional provisional patents for a suppository application to its technology portfolio. It is subject to Federal and state laws, regulations, and recommendations relating to safe working conditions, laboratory practices, the experimental use of animals, and the purchase, storage, movement, import, export, use, and disposal of hazardous or potentially hazardous substances, including radioactive compounds and infectious disease agents, used in connection with research are applicable to its activities.

Top Ranked Articles about Oramed Pharmaceuticals Inc

Something Strange Is Going On With Oral Insulin Novo Nordisk recently abandoned program despite promising results
Something is rotten in the state of Denmark. Read more...

Ratios

vs
industry
vs
history
Price-to-Owner-Earnings 44.16
ORMP's Price-to-Owner-Earnings is ranked higher than
83% of the 138 Companies
in the Global Biotechnology industry.

( Industry Median: 35.58 vs. ORMP: 44.16 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ORMP' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 9.79  Med: 24.58 Max: 45.16
Current: 44.16
9.79
45.16
PB Ratio 5.23
ORMP's PB Ratio is ranked higher than
54% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. ORMP: 5.23 )
Ranked among companies with meaningful PB Ratio only.
ORMP' s PB Ratio Range Over the Past 10 Years
Min: 2.44  Med: 3.57 Max: 5.35
Current: 5.23
2.44
5.35
PS Ratio 64.05
ORMP's PS Ratio is ranked lower than
81% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. ORMP: 64.05 )
Ranked among companies with meaningful PS Ratio only.
ORMP' s PS Ratio Range Over the Past 10 Years
Min: 44.81  Med: 148.37 Max: 930
Current: 64.05
44.81
930
Price-to-Free-Cash-Flow 34.96
ORMP's Price-to-Free-Cash-Flow is ranked higher than
82% of the 141 Companies
in the Global Biotechnology industry.

( Industry Median: 24.99 vs. ORMP: 34.96 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ORMP' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 9.29  Med: 22.61 Max: 35.75
Current: 34.96
9.29
35.75
Price-to-Operating-Cash-Flow 34.96
ORMP's Price-to-Operating-Cash-Flow is ranked higher than
85% of the 191 Companies
in the Global Biotechnology industry.

( Industry Median: 21.01 vs. ORMP: 34.96 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ORMP' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 9.29  Med: 22.61 Max: 35.75
Current: 34.96
9.29
35.75
EV-to-EBIT -9.91
ORMP's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. ORMP: -9.91 )
Ranked among companies with meaningful EV-to-EBIT only.
ORMP' s EV-to-EBIT Range Over the Past 10 Years
Min: -14.3  Med: -9.3 Max: -6.8
Current: -9.91
-14.3
-6.8
EV-to-EBITDA -9.92
ORMP's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. ORMP: -9.92 )
Ranked among companies with meaningful EV-to-EBITDA only.
ORMP' s EV-to-EBITDA Range Over the Past 10 Years
Min: -14.3  Med: -9.3 Max: -6.8
Current: -9.92
-14.3
-6.8
Current Ratio 6.04
ORMP's Current Ratio is ranked higher than
65% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. ORMP: 6.04 )
Ranked among companies with meaningful Current Ratio only.
ORMP' s Current Ratio Range Over the Past 10 Years
Min: 0.13  Med: 7.69 Max: 67.68
Current: 6.04
0.13
67.68
Quick Ratio 6.04
ORMP's Quick Ratio is ranked higher than
67% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. ORMP: 6.04 )
Ranked among companies with meaningful Quick Ratio only.
ORMP' s Quick Ratio Range Over the Past 10 Years
Min: 0.13  Med: 7.69 Max: 67.68
Current: 6.04
0.13
67.68

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -18.40
ORMP's 3-Year Average Share Buyback Ratio is ranked lower than
69% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. ORMP: -18.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ORMP' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -44.9  Med: -18.4 Max: -7.6
Current: -18.4
-44.9
-7.6

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 11.98
ORMP's Price-to-Net-Current-Asset-Value is ranked lower than
63% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. ORMP: 11.98 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ORMP' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.56  Med: 7.89 Max: 94.5
Current: 11.98
2.56
94.5
Price-to-Tangible-Book 5.23
ORMP's Price-to-Tangible-Book is ranked higher than
61% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. ORMP: 5.23 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ORMP' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.19  Med: 6.75 Max: 76.36
Current: 5.23
2.19
76.36
Price-to-Median-PS-Value 0.43
ORMP's Price-to-Median-PS-Value is ranked higher than
82% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. ORMP: 0.43 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ORMP' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.31  Med: 0.99 Max: 4.79
Current: 0.43
0.31
4.79
Earnings Yield (Greenblatt) % -10.09
ORMP's Earnings Yield (Greenblatt) % is ranked lower than
64% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. ORMP: -10.09 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ORMP' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -10054.13  Med: 0 Max: 0
Current: -10.09
-10054.13
0

More Statistics

Revenue (TTM) (Mil) $1.74
EPS (TTM) $ -0.96
Beta1.06
Short Percentage of Float1.86%
52-Week Range $5.70 - 9.09
Shares Outstanding (Mil)13.29

Analyst Estimate

Aug17 Aug18
Revenue (Mil $) 2 3
EPS ($) -0.99 -1.27
EPS without NRI ($) -0.99 -1.27
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for ORMP

Headlines

Articles On GuruFocus.com
Oramed Granted Canadian Patent for GLP-1 Analog Capsule May 09 2017 
Oramed Receives Israel Regulatory Approval to Conduct Human Study for New Oral Leptin Capsule May 02 2017 
Oramed Pharmaceuticals Gaining Strength in Oral Diabetes Market May 01 2017 
Insiders' Week: JPMorgan, Alphabet, Netflix Apr 21 2017 
Oramed Granted European Patent for Combination Oral Insulin and GLP-1 Analog Capsule Apr 20 2017 
Journal of Diabetes Science and Technology Publishes Scientific Paper Authored by Oramed Scientists Apr 04 2017 
While Big Diabetes Stagnates, Smaller Companies Are Moving Faster Than Ever Feb 09 2017 
Something Strange Is Going On With Oral Insulin Dec 23 2016 
Coverage Initiation Report Focuses on Oramed Pharmaceuticals Nov 11 2014 

More From Other Websites
Oramed to Present at Conferences Next Week May 18 2017
Oramed Granted Canadian Patent for GLP-1 Analog Capsule May 09 2017
Oramed Pharmaceuticals, Inc. :ORMP-US: Earnings Analysis: Q2, 2017 By the Numbers : May 5, 2017 May 05 2017
Oramed (ORMP) to Conduct Human Study for New Oral Leptin Capsule May 02 2017
Oramed Receives Israel Regulatory Approval to Conduct Human Study for New Oral Leptin Capsule May 02 2017
Oramed Gaining Strength in Oral Diabetes Market May 01 2017
Oramed Granted European Patent for Combination Oral Insulin and GLP-1 Analog Capsule Apr 20 2017
Oramed reports 2Q loss Apr 06 2017
Journal of Diabetes Science and Technology Publishes Scientific Paper Authored by Oramed Scientists Apr 04 2017
Oramed to Present at Oligonucleotide and Peptide Therapeutics (OPT) Boston Conference on March 28,... Mar 22 2017
Oramed Appoints Dr. Ronald Law as Chief Strategy Officer Mar 21 2017
While Big Diabetes Stagnates, Smaller Companies Are Moving Faster Than Ever Feb 09 2017
Oramed to Present at BIO CEO and Investor and Disruptive Growth and Healthcare Conferences Feb 07 2017
3 Sleeper Biotechs That Could Bounce Back Strong in 2017 Dec 30 2016
Something Strange Is Going On With Oral Insulin Dec 23 2016
ORMP: Oramed Reports Positive Phase Ib Data for ORMD-0901 Nov 30 2016
Oramed's ORMD-0901 (Oral GLP-1 Analog) Found Safe and Well Tolerated in Phase Ib Study Nov 29 2016
Oramed Receives Additional $4 Million Milestone Payment From HTIT Oct 06 2016
Oramed to Present at the Aegis Capital Growth Conference Sep 19 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}